Case Report

Disseminated Mucormycosis with Positive Aspergillus Galactomannan

Despoina Kitmiridou,1 Su N. Aung2, and Dimitrios Farmakiotis2

1Medical Student, National and Kapodistrian University of Athens, Athens, Greece
2Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, USA

Correspondence should be addressed to Su N. Aung; sunandar.aung@lifespan.org and Dimitrios Farmakiotis; dimitrios.farmakiotis@lifespan.org

Received 19 August 2018; Accepted 26 November 2018; Published 24 December 2018

Academic Editor: Larry M. Bush

Copyright © 2018 Despoina Kitmiridou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We describe a case of disseminated mucormycosis (Apophysomyces elegans) diagnosed on autopsy, in a man who had been working in construction with undiagnosed neutropenia from hairy-cell leukemia, which is rarely associated with invasive mold infections. Galactomannan values in both blood and bronchoalveolar lavage were strongly positive. There is an unmet need for accurate noninvasive fungal diagnostic tests. Detailed history, including occupational exposures, can be more informative than laboratory workup.

1. Case Presentation

A 48-year-old man was admitted to the intensive care unit with pneumonia and septic shock. He had no medical history, history of surgeries, or known allergies. He was not taking any medications. He worked as a pipefitter; otherwise, his social history was unremarkable. He had no significant family history. He tested positive for influenza B. He was treated with oseltamivir, vancomycin, piperacillin-tazobactam, and azithromycin. Chest X-ray showed patchy airspace disease in the right lung and focal consolidation in the left. Blood cultures returned positive for Streptococcus pneumoniae.

His absolute neutrophil count was 0, and peripheral flow cell cytometry showed hairy-cell leukemia, for which he received high-dose corticosteroids and rituximab.

He developed anuric acute kidney failure requiring hemodialysis and marked elevation of liver function tests. On day 5, he had new fever, for which piperacillin/tazobactam was changed to meropenem. On day 9, blood cultures were positive for Candida albicans. Caspofungin was added. Chest CT revealed multifocal pneumonia. Bronchoscopy showed erythematous airways with minimal secretions. Bronchoalveolar lavage (BAL) galactomannan was strongly positive in the left lower lobe and negative in the right lower lobe. Serum galactomannan was positive x2 (Figure 1). BAL bacterial and fungal cultures were positive only for C. albicans.

Isavuconazole was added on day 15 for probable invasive aspergillosis in the setting of multiorgan, including kidney (persistently anuric), and liver (bilirubin level of 15 mg/dL), and failure. He had massive hemoptysis and died one day after. Autopsy showed disseminated mucormycosis (Figures 2–4). Culture identified the species as Apophysomyces elegans.

2. Discussion

Although mucormycoses are rare, their frequency is likely underestimated. Most cases have been described in patients with poorly controlled diabetes, those treated with deferoxamine, and mainly in severely immunocompromised patients with history of solid organ or bone marrow transplant, or those neutropenic from acute myeloid or lymphoblastic, rather than hairy-cell leukemia [1]. Our patient, while neutropenic, likely inhaled through occupational exposure high inocula of Apophysomyces spores, which are abundant in soil [1, 2].
Disseminated mucormycosis usually results from progression of a localized (pulmonary) infection with hematogenous spread. It is frequently associated with nonspecific signs and symptoms, and almost always fatal [1]. In this case, high-dose corticosteroids might have accelerated fungal growth and dissemination.

Diagnosis of mucormycosis remains challenging and is often made by biopsy, because the yield of bronchoscopy is extremely low, since hyphae are angioinvasive in tissue, rather than the alveolar space [1]. Our case highlights these important limitations and the fact that galactomannan in blood or BAL has limited specificity and was likely false positive in this case [3]. The positive galactomannan could not have been caused by mucormycosis. In one study, significant Candida burden in the respiratory tract, which our patient had, was proposed as a potential cause of elevated BAL galactomannan [4]. Nevertheless, Candida could not explain the positive serum galactomannan. Another possible explanation, which could not be entirely ruled out without molecular diagnosis, is a mixed mold infection with the mucorales outgrowing Aspergillus, since postinfluenza aspergillosis is a well-described clinical syndrome [5].

In mucormycoses, early initiation of amphotericin-B dramatically increases survival [1, 6]. The newer triazoles posaconazole and isavuconazole are active against the mucorales in vitro and in case series [1]. Although they are less toxic, their efficacy compared to amphotericin-B needs to be better defined.

**3. Conclusions**

Immunocompromised patients are at risk of multiple simultaneous life-threatening infections. Neutropenic patients in the community are at increased risk for invasive mold infection, especially when they have potential exposure to high inocula of spores. BAL cultures and fungal biomarkers may be misleading; thus, a detailed exposure and occupational history can be more informative. In high-risk immunocompromised patients, broad antimold prophylaxis or early empiric treatment should be considered. Novel noninvasive diagnostic modalities for invasive mold infections are urgently needed.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.
References

[1] D. Farmakiotis and D. P. Kontoyiannis, “Mucormycoses,” Infectious Disease Clinics of North America, vol. 30, no. 1, pp. 143–163, 2016.

[2] R. Neblett Fanfair, K. Benedict, J. Bos et al., “Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011,” New England Journal of Medicine, vol. 367, no. 23, pp. 2214–2225, 2012.

[3] D. Farmakiotis, A. Le, Z. Weiss, N. Ismail, D. W. Kubiak, and S. Koo, “False positive bronchoalveolar lavage galactomannan: effect of host and cut-off value,” Mycoses, 2018, In press.

[4] F. Persat, P. Vanon, S. Ranque, and S. Picot, “Candida albicans interferes with galactomannan antigenaemia in human bronchoalveolar lavage fluids,” in Proceedings of 20th European Congress of Clinical Microbiology and Infectious Diseases, pp. S219–S220, Vienna, Austria, April 2010.

[5] L. Vanderbeke, I. Spriet, C. Breynaert, B. J. A. Rijnders, P. E. Verweij, and J. Wauters, “Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment,” Current Opinion in Infectious Diseases, vol. 31, no. 6, pp. 471–480, 2018.

[6] G. Chamilos, R. E. Lewis, and D. P. Kontoyiannis, “Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis,” Clinical Infectious Diseases, vol. 47, no. 4, pp. 503–509, 2008.